# US 2012/0251453 A1 · Methods and Compositions Related to Annexin 1-Binding Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251453 A1
- Document ID: US20120251453A1
- Status: Published application
- Kind: A1
- Application number: 13/515,930
- Filed: 2010-12-23
- Published: 2012-10-04
- Earliest claimed: 2009-12-23
- Assignees: Burnham Institute for Medical Research; Hamamatsu University School of Medicine
- Inventors: Michiko Fukuda; Kazuhiro Sugihara; Naohira Kanayama
- Web page: https://patentgrep.com/patent/US20120251453A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are conjugates comprising the annexin 1-binding peptide IFLLWQR covalently linked to a therapeutic or detectable agent. Also disclosed are compositions comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are isolated nucleic acids comprising a nucleic acid sequence encoding a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods comprising administering to a subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. The disclosed targeting is useful for treatment of, for example, cancer.

## Claims

### Claim 1

A composition comprising a peptide and a moiety, wherein the peptide comprises an amino acid sequence that can bind to a carbohydrate receptor on a cell.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the carbohydrate receptor is annexin 1.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the amino acid sequence can selectively bind the carbohydrate receptor.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the cell is a tumor cell.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the amino acid sequence comprises IFLLWQRX (amino acids 1 to 8 of SEQ ID NO:20), IFLLWQRXX (amino acids 1 to 9 of SEQ ID NO:20), IFLLWQRXXX (amino acids 1 to 10 of SEQ ID NO:20), IFLLWQRXXXX (amino acids 1 to 11 of SEQ ID NO:20), or IFLLWQRXXXXX (SEQ ID NO:20), wherein each X is independently a polar or charged amino acid, wherein the amino acid sequence has none, one, or more conservative amino acid substitutions in IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20).

### Claim 6 (depends on 5)

The composition of claim 5, wherein each X can independently be selected from all, any set of 10, any set of 9, any set of 8, any set of 7, any set of 6, any set of 5, any set of 4, any set of 3, any set of 2, or any 1 of the amino acids C, R, K, S, T, H, D, E, N, Q, and M.

### Claim 7 (depends on 5)

The composition of claim 5, wherein each X can independently be selected from the set of three amino acids C, R, and K.

### Claim 8 (depends on 5)

The composition of claim 5, wherein each X can independently be selected from the set of two amino acids C and R.

### Claim 9 (depends on 5)

The composition of claim 5, wherein a single one of the X in the amino acid sequence is C, two of the X in the amino acid sequence are C, two of the X in the amino acid sequence are R, three of the X in the amino acid sequence are R, four of the X in the amino acid sequence are R, or a compatible combination thereof.

### Claim 10 (depends on 5)

The composition of claim 5, wherein the amino acid sequence consists of IFLLWQRX (amino acids 1 to 8 of SEQ ID NO:20), IFLLWQRXX (amino acids 1 to 9 of SEQ ID NO:20), IFLLWQRXXX (amino acids 1 to 10 of SEQ ID NO:20), IFLLWQRXXXX (amino acids 1 to 11 of SEQ ID NO:20), or IFLLWQRXXXXX (SEQ ID NO:20).

### Claim 11 (depends on 5)

The composition of claim 5, wherein the portion of the amino acid sequence corresponding to the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20) can have at least 55% sequence identity to the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20), wherein differences between the annexin 1-binding compound and IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20) consist of conservative amino acid substitutions.

### Claim 12 (depends on 5)

The composition of claim 5, wherein the portion of the amino acid sequence corresponding to the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20) can have at least 70% sequence identity to the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20).

### Claim 13 (depends on 5)

The composition of claim 5, wherein the portion of the amino acid sequence corresponding to the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20) can have at least 80% sequence identity to the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20).

### Claim 14 (depends on 5)

The composition of claim 5, wherein the annexin 1-binding compound has at least 5 consecutive amino acids of the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20).

### Claim 15 (depends on 5)

The composition of claim 5, wherein the annexin 1-binding compound has at least 6 consecutive amino acids of the sequence IFLLWQR (amino acids 1 to 7 of SEQ ID NO:20).

### Claim 16 (depends on 5)

The composition of claim 5, wherein the amino acid sequence comprises IFLLWQRCR (SEQ ID NO:17), IFLLWQRCRR (SEQ ID NO:19), IFLLWQRCRRR (SEQ ID NO:18), or IFLLWQRCRRRR (SEQ ID NO:22).

### Claim 17 (depends on 5)

The composition of claim 5, wherein the amino acid sequence consists of IFLLWQRCR (SEQ ID NO:17), IFLLWQRCRR (SEQ ID NO:19), IFLLWQRCRRR (SEQ ID NO:18), or IFLLWQRCRRRR (SEQ ID NO:22).

### Claim 18 (depends on 1)

The composition of claim 1, wherein the amino acid sequence comprises SEQ ID NO:2 having none, one, or more conservative amino acid substitutions.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the amino acid sequence has at least 55% sequence identity to SEQ ID NO:2, wherein differences between the amino acid sequence and SEQ ID NO:2 consist of conservative amino acid substitutions.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the amino acid sequence has at least 70% sequence identity to SEQ ID NO:2.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the amino acid sequence has at least 80% sequence identity to SEQ ID NO:2.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the amino acid sequence comprises SEQ ID NO:2.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the peptide comprises SEQ ID NO:2.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the amino acid sequence consists of SEQ ID NO:2.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the amino acid sequence comprises at least 5 consecutive amino acids of SEQ ID NO:2.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the amino acid sequence comprises at least 6 consecutive amino acids of SEQ ID NO:2.

### Claim 27 (depends on 1)

The composition of claim 1, wherein the peptide comprises at least 6 amino acids.

### Claim 28 (depends on 1)

The composition of claim 1, wherein the peptide comprises at least 7 amino acids.

### Claim 29 (depends on 1)

The composition of claim 1, wherein the peptide comprises at least 8 amino acids.

### Claim 30 (depends on 1)

The composition of claim 1, wherein the peptide comprises at least 9 amino acids.

### Claim 31 (depends on 1)

The composition of claim 1, wherein the moiety is a small molecule, pharmaceutical drug, toxin, fatty acid, detectable marker, conjugating tag, nanoshell, or enzyme.

### Claim 32 (depends on 1)

The composition of claim 1, wherein the moiety is covalently linked to the peptide.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the moiety is linked to the amino terminal end of the peptide.

### Claim 34 (depends on 32)

The composition of claim 32, wherein the moiety is linked to the carboxy terminal end of the peptide.

### Claim 35 (depends on 32)

The composition of claim 32, wherein the moiety is linked to an amino acid within the peptide.

### Claim 36 (depends on 1)

The composition of claim 1, further comprising a linker connecting the moiety and the peptide.

### Claim 37 (depends on 1)

The composition of claim 1, wherein the moiety is SN-38, wherein the amino acid sequence does not consist of SEQ ID NO:2.

### Claim 38 (depends on 1)

The composition of claim 1, wherein the moiety is SN-38, wherein the peptide does not consist of SEQ ID NO:2.

### Claim 39 (depends on 1)

The composition of claim 1, wherein the moiety is a cancer chemotherapeutic agent.

### Claim 40 (depends on 1)

The composition of claim 1, wherein the amino acid sequence consists of SEQ ID NO:2.

### Claim 41 (depends on 1)

The composition of claim 1, wherein the peptide consists of SEQ ID NO:2.

### Claim 42 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 43 (depends on 1)

The composition of claim 1, wherein the moiety comprises a therapeutic agent.

### Claim 44 (depends on 1)

The composition of claim 1, wherein the composition further comprises a therapeutic agent.

### Claim 45 (depends on 1)

The composition of claim 1, wherein the moiety comprises a detectable agent.

### Claim 46 (depends on 1)

The composition of claim 1, wherein the moiety comprises a therapeutic agent.

### Claim 47 (depends on 1)

The composition of claim 1, wherein the composition further comprises a detectable agent.

### Claim 48 (depends on 1)

The composition of claim 1, wherein the composition further comprises a therapeutic agent.

### Claim 49 (depends on 1)

The composition of claim 1, wherein the composition further comprises an anti-cancer agent.

### Claim 50 (depends on 1)

An isolated nucleic acid comprising a nucleic acid sequence encoding a peptide and moiety according to claim 1.

### Claim 51 (depends on 1)

A method comprising administering to a subject a composition according to claim 1.

### Claim 52 (depends on 51)

The method of claim 51, wherein the subject comprises a cell, wherein the cell is a tumor cell.

### Claim 53 (depends on 51)

The method of claim 51, wherein the subject is in need of treatment, wherein the administration treats the subject.

### Claim 54 (depends on 53)

The method of claim 53, wherein the subject has cancer, wherein the administration treats the cancer of the subject.

### Claim 55 (depends on 1)

A method of targeting a tumor cell in a subject, the method comprising administering to the subject a composition according to claim 1.

### Claim 56 (depends on 1)

A method comprising administering to the subject a composition according to claim 1 and detecting the composition in the subject.

### Claim 57 (depends on 56)

The method of claim 56, wherein detecting the composition thereby detects a tumor in the subject.

### Claim 58 (depends on 56)

The method of claim 56, wherein detecting the composition thereby diagnoses cancer in the subject.

### Claim 59 (depends on 56)

The method of claim 56, wherein detecting the composition comprises detecting the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject, wherein the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject indicates the prognosis of the cancer in the subject.

### Claim 60 (depends on 56)

The method of claim 56, further comprising repeating the administration and detection at a later time, wherein a change in the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject indicates the progress of the endometriosis in the subject.

### Claim 61 (depends on 56)

The method of claim 56, further comprising repeating the administration and detection following treatment, wherein a change in the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject indicates the progress the treatment of the cancer in the subject.
